Sign in
TerminatedPhase 2

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

Key facts

Who runs it
University of Wisconsin, Madison
Where
Madison, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
49 people enrolled
Started
3 Dec 2012
Ended
24 Dec 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Bevacizumab
  • PRDR
Record updated
25 March 2026
Why it stopped
slow accrual

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Histologically or molecularly confirmed Grade 3 or 4 glioma, IDH mutant or wildtype, as defined by the 2021 WHO guidelines
  • Recurrent disease based on combination of clinical, imaging or histologic confirmation
  • Must have previously received radiation and temozolomide to treat their glioma
  • Bevacizumab naive patients must be > 5 months post completion of initial radiation therapy
  • Bevacizumab exposed patients must be > 3 months post completion of initial radiation therapy
  • Age must be >18years, KPS must be greater than 60
  • Hematology, chemistry and a urinalysis must meet protocol specified criteria

Who cannot take part

  • Uncontrolled hypertension (>160/90mmHg)
  • Prior malignancy unless treated >1 year prior to study and have been without treatment and disease free for 1 yr
  • active second malignancy unless non-melanoma skin cancer or cervical cancer in situ
  • Pregnant or breastfeeding

Where in United States

  • University of Wisconsin Hospital and ClinicsMadison, United States

About the trial

What the trial wants to find out

To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27 fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until time of progression in patients with recurrent high grade gliomas (grade III and grade IV). Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior exposure to bevacizumab.

The 4 groups in the trial

  • Bevacizumab-naïve with recurrent IDH wildtype high grade gliomaExisting treatment, for comparison

    27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression

    Treatment: Bevacizumab and PRDR

  • Bevacizumab-exposed with refractory recurrent IDH wildtype high grade gliomaExisting treatment, for comparison

    27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression

    Treatment: Bevacizumab and PRDR

  • Bevacizumab-naïve with recurrent IDH mutant gliomaExisting treatment, for comparison

    27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression

    Treatment: Bevacizumab and PRDR

  • Bevacizumab-exposed with recurrent IDH mutant gliomaExisting treatment, for comparison

    27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression

    Treatment: Bevacizumab and PRDR

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
25 March 2026